Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846)

S Schirrmacher-Memmel; M Retz; M de Santis; B Brehmer; M Zaiss; A Beeker; U von Verschuer; M Bos; Sascha Pahernik; MO Grimm; S Krause; J Gschwend

Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846)

S Schirrmacher-Memmel, M Retz, M de Santis, B Brehmer, M Zaiss, A Beeker, U von Verschuer, M Bos, Sascha Pahernik, MO Grimm, S Krause, J Gschwend

Department of Urology

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	76-76
Journal	ONKOLOGIE
Volume	36
Publication status	Published - 2013

Cite this

Schirrmacher-Memmel, S., Retz, M., de Santis, M., Brehmer, B., Zaiss, M., Beeker, A., von Verschuer, U., Bos, M., Pahernik, S., Grimm, MO., Krause, S., & Gschwend, J. (2013). Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846). ONKOLOGIE , 36, 76-76.

Schirrmacher-Memmel, S ; Retz, M ; de Santis, M et al. / Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846). In: ONKOLOGIE 2013 ; Vol. 36. pp. 76-76.

@article{30f38eff97044c68b453c0f76b5b5d61,

title = "Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846)",

author = "S Schirrmacher-Memmel and M Retz and {de Santis}, M and B Brehmer and M Zaiss and A Beeker and {von Verschuer}, U and M Bos and Sascha Pahernik and MO Grimm and S Krause and J Gschwend",

year = "2013",

language = "English",

volume = "36",

pages = "76--76",

journal = "ONKOLOGIE ",

issn = "0378-584X",

}

Schirrmacher-Memmel, S, Retz, M, de Santis, M, Brehmer, B, Zaiss, M, Beeker, A, von Verschuer, U, Bos, M, Pahernik, S, Grimm, MO, Krause, S & Gschwend, J 2013, 'Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846)', ONKOLOGIE , vol. 36, pp. 76-76.

Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846). / Schirrmacher-Memmel, S; Retz, M; de Santis, M et al.
In: ONKOLOGIE , Vol. 36, 2013, p. 76-76.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846)

AU - Schirrmacher-Memmel, S

AU - Retz, M

AU - de Santis, M

AU - Brehmer, B

AU - Zaiss, M

AU - Beeker, A

AU - von Verschuer, U

AU - Bos, M

AU - Pahernik, Sascha

AU - Grimm, MO

AU - Krause, S

AU - Gschwend, J

PY - 2013

Y1 - 2013

M3 - Abstract (Journal)

SN - 0378-584X

VL - 36

SP - 76

EP - 76

JO - ONKOLOGIE

JF - ONKOLOGIE

ER -

Schirrmacher-Memmel S, Retz M, de Santis M, Brehmer B, Zaiss M, Beeker A et al. Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma - design of the SWITCH-2 Study (NCT01613846). ONKOLOGIE . 2013;36:76-76.